11/11/2005

CIS Biotech, Inc.

Atlanta Biotech Company partners with Bayer

CIS Biotech, Inc., the Atlanta-based medical laboratory research and development firm that has brought stroke diagnostic tools to the market, announces that it has entered into agreements with Bayer HealthCare, Diagnostics Division, a member of the Bayer Group (NYSE:BAY), that will allow the two companies to collaborate on the commercialization of automated serum assays for stroke testing.

“Bayer recognizes that there is a tremendous unmet need for more accurate and accessible diagnosis of stroke and is very excited by the potential to significantly impact the health of stroke patients by bringing this unique biomarker to market,” stated John Blackwood, Vice President for Global Business Development, Bayer HealthCare, Diagnostics Division.

“With their proven success in delivering innovative assays for the cardiovascular market, Bayer is an ideal partner with whom to pursue this important development opportunity,” stated Robert R. Rhinehart, Chairman and CEO of CIS Biotech.

CIS Biotech now starts the process of transferring its technologies to the automated system; clinical trials will follow, in advance of FDA approval of the company’s biomarkers for stroke risk assessment.